Well, as you can imagine, it’s not all “rainbows and lollipops” in cancer research..
A drug that doctors were hoping would extend the lives of those with the most-common type of adult brain cancer has shown no benefit in a large study.
Researchers compared Avastin — generically called bevacizumab — to a placebo in more than 600 patients with glioblastoma and found similar survival rates. Worsened quality of life and a decline in cognitive function were more common in the group that received the drug…
The results point to a need to better understand how to personalize care for brain-cancer patients and figure out which ones — based on genetics and other factors — might respond best to which drugs, said Dr. Arnab Chakravarti, who had a leading role in the study and is chairman of radiation oncology at Ohio State University’s Comprehensive Cancer Center.
Unfortunately, that’s the way it goes too often, and why clinical trials are so critical to cancer care. As Dr Chakravarti states, it also highlights the need for a ‘personalized’ treatment protocol.
On the brighter side, The James has developed into a “destination” location for top cancer researchers this past decade.
“We’ve become a talent magnet,” he adds. “Cancer experts from all over the country are flocking here to be part of a world-class cancer-fighting team. If you talk to the physicians who are here now, they’ll tell you that this is one of the best places in the country and in the world.
“It’s one of the jewels in the crown of cancer care and cancer research.”
Click on the link to see the article and see the short video with Dr Michael Caligiuri. (Dr. Caligiuri is from Buffalo.. just thought that I’d throw that in. You’re welcome..) Read More